Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients

Area of Science:

• Pharmacology
• Transplantation Medicine
• Infectious Diseases

Background:

• Invasive fungal infections pose a significant risk to lung transplant recipients.
• Mold-active azole antifungals are a cornerstone for prophylaxis in this vulnerable population.
• Individual azole agents possess distinct pharmacologic profiles necessitating careful selection.

Purpose of the Study:

• To review the pharmacologic considerations of commonly used azole antifungals in lung transplant recipients.
• To compare voriconazole, posaconazole, and isavuconazole regarding drug interactions, adverse events, and pharmacokinetics.
• To highlight the importance of therapeutic drug monitoring in this specific patient group.

Main Methods:

• Literature review focusing on voriconazole, posaconazole, and isavuconazole.
• Analysis of pharmacokinetic data, drug-drug interactions, and adverse reaction profiles.
• Emphasis on studies involving post-lung transplant patients.

Main Results:

• Voriconazole, posaconazole, and isavuconazole differ in their interaction profiles and pharmacokinetic properties.
• Therapeutic drug monitoring is essential for optimizing voriconazole and posaconazole therapy.
• Emerging data supports isavuconazole's utility, though monitoring strategies are still evolving.

Conclusions:

• Optimizing azole antifungal therapy in lung transplant recipients requires a thorough understanding of individual drug pharmacologies.
• Careful consideration of drug interactions and adverse events is critical for patient safety and treatment efficacy.
• Personalized therapy guided by pharmacokinetic principles and therapeutic drug monitoring can improve outcomes in lung transplant recipients.